Abstract
Miltefosine is a novel antileishmanial drug that has significant selectivity in both in vitro and in vivo models. Clinical efficacy was demonstrated for the treatment of visceral leishmaniasis with the advantage of oral administration over the currently recommended antileishmanial drugs that require parenteral administration. Miltefosine produces high cure rates also in patients resistant to the standard antimonial therapy.
Similar content being viewed by others
References
Achterberg V, Gercken G (1987) Cytotoxicity of ester and ether lysophospholipids on Leishmania donovani promastogotes. Mol Biochem Parasitol 23:117–122
Achterberg V, Gercken G (1987) Metabolism of ether lyophospholipids in Leishmania donovani promastigotes. Mol Biochem Parasitol 26:277–287
Berman JD (1991) Biological mechanisms of clinical antileishmanial agents: a review. J Cell Pharmacol 2:85–82
Berman JD (1997) Human leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin Infect Dis 24:684–703
Bryceson ADM, Chulay JD, Ho M, Mugambii M, Were JB (1985) Visceral leishmaniasis unresponsive to antimonial drugs. I. Clinical and immunological studies. Trans R Soc Trop Med Hyg 79:700–704
Bryceson ADM (1987) Therapy in man. In: Peters W, Killick-Kendrick R (eds) The leishmaniasis in biology and medicine, Vol 2. Academic Press, New York, pp 848–907
Burdzy K, Munder PG, Fischer H, Westphal O (1964) Steigerung der Phagozytose von Perionialmagrophagen durch Lysolecithin. Z Naturforsch 19B:1118
Croft SL, Neal RA, Pendergast W, Chan JH (1987) The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani. Biochem Pharmacol 36:2633–2636
Croft SL, Neal RA, Thornton E, Herrmann DBJ (1993) Antileishmanial activity of the ether phospholipid ilmofosine. Trans R Soc Trop Med Hyg 87:217–219
Croft SL, Snowdon D, Yardley V (1996) The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J Antimicrob Chemother 38:1041–1047
Davidson RN, Di Martino L, Gradoni L, Giacchino R (1994) Liposomal amphotericin B (Am Bisome) in Mediteranian visceral leishmaniasis: a multicenter trial. Q J Med 87:75–81
Davidson RN (1998) Practical guide for the treatment of leishmaniasis. Drug 56:1009–1018
Desjeux P (1996) Leishmaniasis: public health aspects and control. Clin Dermatol 14:417–423
Dietze R, Milan EP, Berman JD, Grogl M (1993) Treatment of Brazilian Kala-Azar with a short course of Amphocil (Amphotericin B-chlolesterol dispersion). Clin Infect Dis 17:981–986
Dogra J (1991) A double-blind study on the efficacy of oral Dapsone in cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 85:212–213
Escobar P, Yardley V, Croft SL (2001) Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 45:1872–1875
Escobar P, Matu S, Marques C, Croft SL (2002) Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH3 (edelfosine) and amphotericin B. Acta Trop 81:151–157
Gokhale PC, Kshirsagar NA, Khan MU, Pandya SK (1994) Successful treatment of resistant visceral Leishmaniasis with liposomal Amphotericin B. Trans R Soc Trop Med Hyg 88:228
Grevelink SA, Lerner EA (1996) Leishmaniasis. J Am Acad Dermatol 34:257–272
Grogl M, Oduola AMJ, Cordero LDC, Kyle DE (1989) Leishmania spp: development of Pentostam resistant clones in vitro by discontinuous drug exposure. Exp Parasitol 69:78–90
Harms G, Zwingenberger K, Sandkamp B, Omena S, Pedrosa C, Richter J, Rosenkaimer F (1993) Immunochemotherapy of visceral leishmaniasis. A pilot trial of sequential treatment with recombinant interferon-gamma and pentavalent antimony. J Interferon Res 13:39–41
Hepburn NC, Nolan J, Fenn L, Herd RM, Neilson JMM (1994) Cardiac effects of sodium stibogluconate. Q J Med 87:465–472
Herwaldt BL (1999) Miltefosine—the long-awaited therapy for visceral leishmaniasis? N Engl J Med 341:1840–1842
Hilgard P, Stekar J, Voegeli R, Engel J, Schumacher W, Eibl HJ, Unger C, Berger MR (1988) Characterization of the antitumor activity of hexadecylphosphocholine (D-18506). Eur J Cancer Clin Oncol 24:1457–1461
Hilgard P, Kampherm E, Nolan L, Pohl J, Reissmann T (1991) Investigation into the immunological effects of miltefosine, a new anticancer agent under development. J Cancer Res Clin Oncol 117:403–408
Hochhuth CH, Vehmeyer K, Eibl HJ, Unger C (1992) Hexadecylphosphocholine induces interferone-γ secretion and expression of GM-CSF mRNA in human mononuclear cells. Cell Immunol 141:161–168
Jha TK, Giri YN, Singh TK, Jha S (1995) Use of amphotericin B in drug resistant cases of visceral leishmaniasis in north Bihar, India. Am J Trop Med Hyg 52:536–538
Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795–1800
Klenner T, Beckers T, Nooter K, Holtmann H (1996) Influence of hexadecylphosphocholine (Miltefosine) on cytokine synthesis and biological responses. Adv Exp Med Biol 416:181–187
Kuhlencord A, Maniera T, Eibl H, Unger C (1992) Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob Agents Chemother 36:1630–1634
Le Fichoux Y, Rousseau D, Ferrua B, Ruette S, Lelievre A, Grousson D, Kubar J (1998) Short- and long-term efficacy of hexadecylphosphocholine against established Leishmania infantum infection in BALB/c mice. Antimicrob Agents Chemother 42:654–658
Lira R, Sundar S, Makharia A, et al (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony resistantstrains of Leishmania donovani. J Infect Dis 180:564
Lira R, Contreras LM, Santa-Rita RM, Urbina JA (2001) Mechanism of action of anti-proliferative lysophospholipid analogues against the protozoan parasite Trypanosoma cruzi: potentiation of the in-vitro activity by the sterol biosynthesis inhibitor ketoconazole. J Antimicrob Chemother 47:537–546
Lux H, Hart DT, Parker PJ, Klenner T (1996) Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for antileishmanial alkyl phospholipid analogues. Adv Exp Med Biol 416:201–211
Lux H, Heise N, Klenner T, Hart D, Opperdoes FR (2000) Ether-lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol Biochem Parasitol 111:1–14
McBride M, Linney M, Claydon EJ, Weber J (1994) Visceral leishmaniasis following treatment with liposomal amphotericin B. Clin Infect Dis 19:362
Murray HW, Squires KE, Harms G, Rosenkaimer F (1992) Clinical trials of interferon-gamma for leishmaniasis. In: Sonnenfeld G, Czarniecki C, Nacy C, et al (eds) Cytokines and resistance to nonviral infections. Biomedical Press, Augusta, pp 199–206
Murray HW (2000) Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T-cell-deficient mice by oral miltefosine. Antimicrob Agents Chemother 44:3235–3236
Murray HW, Delph-Etienne S (2000) Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J Infect Dis 181:795–799
Safa O, Parkin SM, Matthew AM, Bibby MC (1997) Morphological and immunological observations on the effects of hexadecylphosphocholine (HPC) in nude mice bearing MT-1 breast cancer xenografts. Anticancer Res 17:37–44
Santa-Rita RM, Barbosa HS, Meirelles MNSL, Castro SL de (2000) Effect of the alkyl-lysophospholipids on the proliferation and differentiation of Trypanosoma cruzi. Acta Trop 75:219–228
Schmidt-Ott R, Klenner T, Overath P, Aebischer T (1999) Topical treatment with hexadecylphosphocholine (Miltex®) efficiently reduces parasite burden in experimental cutaneous leishmaniasis. Trans R Soc Trop Med Hyg 93:85–90
Soto J, Toledo J, Gutierrez P, Nicholis RS, Padilla J, Engel J, Fischer C, Voss A, Berman J (2001) Treatment of American cutaneous leishmaniasis with Miltefosine, an oral agent. Clin Infect Dis 33:E57–E61
Squires KE, Rosenkaimer F, Sherwood JA, Were JBO, Murray HW (1993) Immunochemotherapy for visceral Leishmaniasis. A controlled pilot trial of antimony versus antimony plus interferon-gamma. Am J Trop Med Hyg 48:666–669
Sundar S, Rosenkaimer F, Murray HW (1994) Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J Infect Dis 170:659–662
Sundar S, Rosenkaimer F, Lesser ML, Murray HW (1995) Immunochemotherapy for a systemic intracellular infection: accelerated response using interferon-gamma in visceral leishmaniasis J Infect Dis 171:992–996
Sundar S, Rosenkaimer F, Makharia MK, Goyal AK, Mandal AK, Voss A, Hilgard P, Murray HW (1998) Trial of miltefosine for visceral leishmaniasis. Lancet 352:1821–1823
Sundar S, Gupta LB, Makharia MK, Singh MK, Voss A, Rosenkaimer F, Engel J, Murray HW (1999) Oral treatment of visceral leishmaniasis with miltefosine. Ann Trop Med Parasitol 93:589–597
Sundar S, Makharia A, More DK, Agraval G, Voss A, Fischer C, Bachmann P, Murray HW (2001) Short course of oral miltefosine for treatment of visceral leishmaniasis. Clin Infect Dis 31:1110–1113
Sundar S, Jha TK, Thakur CP, Engel J, Sindermann H, Fischer C, Junge K, Bryceson A, Berman J (2002) Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med 347:1739–1746
Sundar S, Jha TK, Sindermann H, Junge K, Bachmann P, Berman J (2003) Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasis. Pediatr Infect Dis J 22:434–438
Teklemariam S, Hiwot AG, Frommel D, Miko TL (1994) Aminosidine and its combination with sodium stibogluconate in the treatment of diffuse cutaneous leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 88:334–339
Thakur CP, Kumar M, Pandey AK (1991) Evaluation of efficacy of longer durations of therapy for fresh cases of kala-azar with sodium stibogluconate. Indian J Med Res 92:103–120
Thakur CP, Olliaro P, Gothoskar S, Bhowmick S (1992) Treatment of visceral leishmaniasis (kala-azar) with aminosidine (paromomycine)-antimonial combinations, a pilot study in Bihar, India. Trans R Soc Trop Med Hyg 86:615–616
Tsushima S, Yoshioka Y, Tanida S, Nomura H, Nojima S, Hozumi M (1982) Syntheses and antimicrobial activities of alkyl lysophospholipids. Chem Pharm Bull (Tokyo) 30:3260–3270
Unger C, Maniera T, Kaufmann-Kolle P, Eibl H (1998) In vivo antileishmanial activity of hexadecylphosphocholine and other alkylphosphocholines. Drugs Today 34 (Suppl F):133–140
Verweij J, Plating A, Berg M van der, Stoter G (1992) A dose finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumors. J Cancer Res Clin Oncol 118:606–608
Wilcocks C, Manson-Bahr PEC (1972) Manon's tropical diseases. Baillière Tindall, London, pp 119–133
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sindermann, H., Croft, S.L., Engel, K.R. et al. Miltefosine (Impavido): the first oral treatment against leishmaniasis. Med Microbiol Immunol 193, 173–180 (2004). https://doi.org/10.1007/s00430-003-0201-2
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00430-003-0201-2